540 related articles for article (PubMed ID: 28092665)
21. Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor.
Alam SM; Cronin K; Parks R; Anasti K; Ding H; Go EP; Desaire H; Eaton A; Montefiori D; Sodroski J; Kappes J; Haynes BF; Saunders KO
J Virol; 2020 Oct; 94(21):. PubMed ID: 32817216
[TBL] [Abstract][Full Text] [Related]
22. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
[TBL] [Abstract][Full Text] [Related]
23. V1/V2 Neutralizing Epitope is Conserved in Divergent Non-M Groups of HIV-1.
Morgand M; Bouvin-Pley M; Plantier JC; Moreau A; Alessandri E; Simon F; Pace CS; Pancera M; Ho DD; Poignard P; Bjorkman PJ; Mouquet H; Nussenzweig MC; Kwong PD; Baty D; Chames P; Braibant M; Barin F
J Acquir Immune Defic Syndr; 2016 Mar; 71(3):237-45. PubMed ID: 26413851
[TBL] [Abstract][Full Text] [Related]
24. NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients.
Johansson SE; Rollman E; Chung AW; Center RJ; Hejdeman B; Stratov I; Hinkula J; Wahren B; Kärre K; Kent SJ; Berg L
Viral Immunol; 2011 Oct; 24(5):359-68. PubMed ID: 21958370
[TBL] [Abstract][Full Text] [Related]
25. Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds.
Madani N; Princiotto AM; Easterhoff D; Bradley T; Luo K; Williams WB; Liao HX; Moody MA; Phad GE; Vázquez Bernat N; Melillo B; Santra S; Smith AB; Karlsson Hedestam GB; Haynes B; Sodroski J
J Virol; 2016 May; 90(10):5031-5046. PubMed ID: 26962221
[TBL] [Abstract][Full Text] [Related]
26. Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual.
Montefiori DC; Altfeld M; Lee PK; Bilska M; Zhou J; Johnston MN; Gao F; Walker BD; Rosenberg ES
J Immunol; 2003 Apr; 170(7):3906-14. PubMed ID: 12646660
[TBL] [Abstract][Full Text] [Related]
27. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.
Burton DR; Hessell AJ; Keele BF; Klasse PJ; Ketas TA; Moldt B; Dunlop DC; Poignard P; Doyle LA; Cavacini L; Veazey RS; Moore JP
Proc Natl Acad Sci U S A; 2011 Jul; 108(27):11181-6. PubMed ID: 21690411
[TBL] [Abstract][Full Text] [Related]
28. Combination anti-HIV antibodies provide sustained virological suppression.
Sneller MC; Blazkova J; Justement JS; Shi V; Kennedy BD; Gittens K; Tolstenko J; McCormack G; Whitehead EJ; Schneck RF; Proschan MA; Benko E; Kovacs C; Oguz C; Seaman MS; Caskey M; Nussenzweig MC; Fauci AS; Moir S; Chun TW
Nature; 2022 Jun; 606(7913):375-381. PubMed ID: 35650437
[TBL] [Abstract][Full Text] [Related]
29. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.
Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768869
[TBL] [Abstract][Full Text] [Related]
30. Anti-P30-52 monoclonal antibody cross-reacted to Env V3 and inhibited the viral multiplication of HIV-1-infected MT-4 cells.
Ota A; Bautista AN; Yadav ML; Ueda S
Hybridoma; 1999 Apr; 18(2):139-47. PubMed ID: 10380013
[TBL] [Abstract][Full Text] [Related]
31. A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies.
Davis-Gardner ME; Alfant B; Weber JA; Gardner MR; Farzan M
mBio; 2020 Jan; 11(1):. PubMed ID: 31937648
[TBL] [Abstract][Full Text] [Related]
32. Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals.
Bar-On Y; Gruell H; Schoofs T; Pai JA; Nogueira L; Butler AL; Millard K; Lehmann C; Suárez I; Oliveira TY; Karagounis T; Cohen YZ; Wyen C; Scholten S; Handl L; Belblidia S; Dizon JP; Vehreschild JJ; Witmer-Pack M; Shimeliovich I; Jain K; Fiddike K; Seaton KE; Yates NL; Horowitz J; Gulick RM; Pfeifer N; Tomaras GD; Seaman MS; Fätkenheuer G; Caskey M; Klein F; Nussenzweig MC
Nat Med; 2018 Nov; 24(11):1701-1707. PubMed ID: 30258217
[TBL] [Abstract][Full Text] [Related]
33. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.
Wu X; Wang C; O'Dell S; Li Y; Keele BF; Yang Z; Imamichi H; Doria-Rose N; Hoxie JA; Connors M; Shaw GM; Wyatt RT; Mascola JR
J Virol; 2012 May; 86(10):5844-56. PubMed ID: 22419808
[TBL] [Abstract][Full Text] [Related]
34. Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.
Mayer KH; Seaton KE; Huang Y; Grunenberg N; Isaacs A; Allen M; Ledgerwood JE; Frank I; Sobieszczyk ME; Baden LR; Rodriguez B; Van Tieu H; Tomaras GD; Deal A; Goodman D; Bailer RT; Ferrari G; Jensen R; Hural J; Graham BS; Mascola JR; Corey L; Montefiori DC; ;
PLoS Med; 2017 Nov; 14(11):e1002435. PubMed ID: 29136037
[TBL] [Abstract][Full Text] [Related]
35. HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies.
Lynch RM; Wong P; Tran L; O'Dell S; Nason MC; Li Y; Wu X; Mascola JR
J Virol; 2015 Apr; 89(8):4201-13. PubMed ID: 25631091
[TBL] [Abstract][Full Text] [Related]
36. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
[TBL] [Abstract][Full Text] [Related]
37. Temporal development and prognostic value of antibody response to the major neutralizing epitopes of gp120 during HIV-1 infection.
Turbica I; Simon F; Besnier JM; LeJeune B; Choutet P; Goudeau A; Barin F
J Med Virol; 1997 Jul; 52(3):309-15. PubMed ID: 9210041
[TBL] [Abstract][Full Text] [Related]
38. Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody.
Trott M; Weiβ S; Antoni S; Koch J; von Briesen H; Hust M; Dietrich U
PLoS One; 2014; 9(5):e97478. PubMed ID: 24828352
[TBL] [Abstract][Full Text] [Related]
39. Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex.
Gift SK; Leaman DP; Zhang L; Kim AS; Zwick MB
J Virol; 2017 Dec; 91(24):. PubMed ID: 28978711
[TBL] [Abstract][Full Text] [Related]
40. Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption.
Bar KJ; Sneller MC; Harrison LJ; Justement JS; Overton ET; Petrone ME; Salantes DB; Seamon CA; Scheinfeld B; Kwan RW; Learn GH; Proschan MA; Kreider EF; Blazkova J; Bardsley M; Refsland EW; Messer M; Clarridge KE; Tustin NB; Madden PJ; Oden K; O'Dell SJ; Jarocki B; Shiakolas AR; Tressler RL; Doria-Rose NA; Bailer RT; Ledgerwood JE; Capparelli EV; Lynch RM; Graham BS; Moir S; Koup RA; Mascola JR; Hoxie JA; Fauci AS; Tebas P; Chun TW
N Engl J Med; 2016 Nov; 375(21):2037-2050. PubMed ID: 27959728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
